Triad Life Sciences: Closes A$25M Funding

Triad Life Sciences Closes A$25M Funding

  • Triad Life Sciences, a Memphis, Tenn.-based biotech company, raised AUS$25m funding round
  • The convertible note placement was led by Cannacord Genuity
  • The company intends to use the funds for its US sales force expansion plans, R&D activities, and general working capital needs
  • Triad now plans to move forward with a listing on the Australian Securities Exchange (ASX) in the coming months
  • Led by CEO Russ Olsen, TriadLife Sciences is a biotech company focused on developing and commercializing biomaterials for treating complex surgical and chronic wounds
  • Triad recently received FDA clearance to market InnovaMatrix™, a next generation extracellular matrix (ECM) wound care device
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Brink’s Strengthens Position with $6.6B NCR Acquisition

Brink's expands its services through strategic acquisition of NCR's Atleos.Highlights: Brink's acquires NCR Atleos for $6.6 billion.The deal...

Barclays Strengthens Blockchain Payments Platform Discussions

Bank explores blockchain vendors for enhanced payment solutions.Highlights: Barclays explores blockchain technology for payments.Bank engages with various vendors...

Lloyds Tightens Bank Account Opening Process in Branches

The bank limits account openings amidst ongoing service updates.Highlights: Lloyds will restrict opening some bank accounts in branches.The...

Jack Dorsey’s Block to Lay Off 4,000 Employees as AI Era Advances

Significant workforce reduction reflects shifts in technology focus.Highlights: Block announces 4,000 layoffs amid evolving AI landscape.The decision comes...